Cancer Incidence Associated with Screening and Overdiagnosis
- PMID: 37395477
- DOI: 10.1097/XCS.0000000000000797
Cancer Incidence Associated with Screening and Overdiagnosis
Comment in
-
Quantifying Missed Cancer Incidence Associated with Screening During the Pandemic: In Reply to Jatoi.J Am Coll Surg. 2023 Nov 1;237(5):795-796. doi: 10.1097/XCS.0000000000000798. Epub 2023 Jul 3. J Am Coll Surg. 2023. PMID: 37395478 No abstract available.
Comment on
-
Delay and Disparity in Observed vs Predicted Incidence Rate of Screenable Cancer During the COVID-19 Pandemic.J Am Coll Surg. 2023 Sep 1;237(3):420-430. doi: 10.1097/XCS.0000000000000772. Epub 2023 May 25. J Am Coll Surg. 2023. PMID: 37227063
References
-
- Romatoski KS, Chung SH, Kenzik K, et al. Delay and disparity in observed vs predicted incidence rate of screenable cancer during the COVID-19 pandemic. J Am Coll Surg. 2023;237:420–430.
-
- Jatoi I, Pinsky PF. Breast cancer screening trials: endpoints and overdiagnosis. J Natl Cancer Inst. 2021;113:1131–1135.
-
- Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102:605–613.
-
- Kalager M, Wieszczy P, Lansdorp-Vogelaar I, et al. Overdiagnosis in colorectal cancer screening: time to acknowledge a blind spot. Gastroenterology. 2018;155:592–595.
-
- Patz EF Jr, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174:269–274.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
